MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
